Method for treating lung cancer using a combination of an anti-PD-1 antibody and another anticancer agent

摘要

The present invention provides a method for treating a subject suffering from lung cancer that specifically binds to a therapeutically effective amount of (a) a programmed cell death-1 (PD-1) receptor. An anti-cancer agent that is an antibody or antigen-binding portion thereof that inhibits PD-1 activity (can be administered by infusion for less than 60 minutes); and, optionally, (b) another anti-cancer agent (for less than 90 minutes, Administering to the subject. The other anticancer agent can be an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody.